Fundraising Fox
Bioventrix
Mansfield, US · Delaware corporation · 1 known investors
Find your way into Bioventrix
Sign up to see every warm intro you have to Bioventrix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bioventrix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioVentrix is a medical device company that develops less invasive therapies to treat heart failure by reconstructing the dilated left ventricle using myocardial micro-anchor implants. The company serves cardiothoracic surgeons and patients with ischemic heart failure.
Founders & leadership
DR
DAVID RICHMONDChief Executive OfficerDavid Richmond is Executive Officer and Director at BioVentrix, a medical device company developing less invasive therapies for heart failure. He founded Richmond Brothers, Inc. in 1994, a firm specializing in private equity, philanthropic financial planning, and investment advisory services.
SC
STEVE CHARTIERPresident and Co-CEOSteve Chartier is an executive at BioVentrix with experience in medical device operations, regulatory affairs, quality assurance, and supply chain management across startup and mid-sized organizations.
JD
JAMES DILLONExecutive
OB
ORI BEN-YEHUDAExecutive
WA
WILLIAM ABBOTTChief Financial Officer2019–2024William Abbott is CFO and VP of Finance at BioVentrix, bringing over 30 years of financial leadership experience across medical device, technology, and life sciences sectors. His background includes managing acquisitions and corporate transactions, public company finance and SEC reporting, and roles at companies including Cardiogenesis Corporation.
MK
Miller KenExecutive
RP
Rishi PuriNamed on SEC filing
MR
Mark RavichNamed on SEC filing
WA
William AbrahamNamed on SEC filing
Board
MT
Michael TaglichBoard director
AH
ANDREW HINSONBoard director
BC
BIHUA CHENBoard director
Investors · 1
Andera Partnerslisted by Andera PartnersParis
How we know: Andera Partners's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$176.8M disclosed across 17 of 18 rounds · 2012–2026
▶$1.2MraisedOct 2026 · 6 investors · BiotechnologyRule 506(b)
▶$1.2MraisedOct 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven ChartierExecutive Officer, Director
- Dave RichmondExecutive Officer, Director
- Rishi PuriDirector
- Mark RavichDirector
- William AbrahamDirector
- Offering amount
- $3M
- Amount sold
- $1.2M
- Minimum investment
- $50K
- Proceeds to insiders
- $500K
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2026 · 25 investors · OtherRule 506(b)
▶$3MraisedSep 2026 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David RichmondExecutive Officer, Director
- Steven ChartierExecutive Officer, Director
- Rishi PuriDirector
- William T. AbrahamDirector
- Offering amount
- $10M
- Amount sold
- $3M
- Proceeds to insiders
- $500K
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedNov 2025 · 45 investors · OtherRule 506(b)
▶$6.7MraisedNov 2025 · 45 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- WILLIAM ABRAHAMDirector
- STEVEN CHARTIERExecutive Officer, Director
- RISHI PURIDirector
- DAVID RICHMONDExecutive Officer, Director
- MICHAEL TAGLICHDirector
- MARK RAVICHDirector
- Offering amount
- $12M
- Amount sold
- $6.7M
- Sales commissions
- $120K
- Proceeds to insiders
- $800K
- Placement agents
- FINALIS SECURITIES LLC, THIRD500, LLC, THE BENCHMARK COMPANY, LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedAug 2024 · 21 investors · OtherRule 506(b)
▶$3MraisedAug 2024 · 21 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL TAGLICHDirector
- DAVID RICHMONDExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Proceeds to insiders
- $300K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.7MraisedApr 2023 · 12 investors · OtherRule 506(b)
▶$12.7MraisedApr 2023 · 12 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- RAYMOND COHENDirector
- STEVE CHARTIERExecutive Officer
- JAMES DILLONExecutive Officer, Director
- DAVID RICHMONDDirector
- ANDREW HINSONDirector
- ANDREW COATSDirector
- BIHUA CHENDirector
- MICHAEL TAGLICHDirector
- RAPHAEL WISNIEWSKIDirector
- RINDA SAMADirector
- ORI BEN-YEHUDAExecutive Officer
- WILLIAM ABBOTTExecutive Officer
- CHRISTOPHER WOLFFExecutive Officer
- Offering amount
- $15.7M
- Amount sold
- $12.7M
- Proceeds to insiders
- $1.2M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJan 2023 · 18 investors · OtherRule 506(b)
▶$2MraisedJan 2023 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- STEVE CHARTIERExecutive Officer
- MICHAEL TAGLICHDirector
- ANDREW COATSDirector
- DAVID RICHMONDDirector
- RAYMOND COHENDirector
- ANDREW HINSONDirector
- JAMES DILLONExecutive Officer, Director
- LAUREN BAKERDirector
- WILLIAM ABBOTTExecutive Officer
- GEORGE FAZIODirector
- MARK RAVICHDirector
- CHRISTOPHER WOLFFExecutive Officer
- STEVEN HEALYDirector
- RINDA SAMADirector
- Offering amount
- $3M
- Amount sold
- $2M
- Sales commissions
- $240K
- Proceeds to insiders
- $2M
- Placement agents
- TAGLICH BROTHERS, INC.
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedApr 2022 · 1 investors · OtherRule 506(b)
▶$1MraisedApr 2022 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- STEVE CHARTIERExecutive Officer
- RINDA SAMADirector
- JAMES DILLONExecutive Officer, Director
- CHRISTOPHER WOLFFExecutive Officer
- GEORGE FAZIODirector
- STEVEN HEALYDirector
- MARK RAVICHDirector
- ANDREW COATSDirector
- THASEEGARAN PILLAY, M.D.Executive Officer
- DAVID RICHMONDDirector
- ANDREW HINSONDirector
- WILLIAM ABBOTTExecutive Officer
- MICHAEL TAGLICHDirector
- RAYMOND COHENDirector
- Offering amount
- $10M
- Amount sold
- $1M
- Sales commissions
- $700K
- Proceeds to insiders
- $2M
- Placement agents
- TAGLICH BROTHERS, INC.
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJan 2022 · 5 investors · OtherRule 506(b)
▶$6MraisedJan 2022 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- MARK RAVICHDirector
- WILLIAM ABBOTTExecutive Officer
- STEVEN HEALYDirector
- MICHAEL TAGLICHDirector
- JAMES DILLONExecutive Officer, Director
- GEORGE FAZIODirector
- DAVID RICHMONDDirector
- RAYMOND COHENDirector
- RINDA SAMADirector
- ANDREW HINSONDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Ancora HeartAncora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
Alleviant Medical IncAlleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
Companies working in the same space as Bioventrix.
Frequently asked questions
- What does Bioventrix do?
- BioVentrix is a medical device company that develops less invasive therapies to treat heart failure by reconstructing the dilated left ventricle using myocardial micro-anchor implants. The company serves cardiothoracic surgeons and patients with ischemic heart failure.
- Who are Bioventrix's investors?
- Bioventrix's investors include Andera Partners.
- How much funding has Bioventrix raised?
- Bioventrix has disclosed $176.8M raised across 17 of its 18 known rounds.
- Where is Bioventrix headquartered?
- Bioventrix is headquartered in Mansfield, US.